- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04431440
Silver Nanoparticles in Multidrug Resistant Bacteria
November 4, 2020 updated by: Rasha Hamed, Assiut University
Bactericidal Effect of Silver Nanoparticles on Methecillin and Vancomycin Resistant Staphylococcus. Aureus (MRSA) Isolated From Critically Ill Patients
Recently, silver nanoparticles (AgNPs) have been widely used in various applications as antimicrobial agents, anticancer, diagnostics, biomarkers, cell labels, and drug delivery systems for the treatment of various diseases.
The present study investigated the bactericidal effect of AgNPs against Methecillin Resistant Staph.
aureus (MRSA) and Vancomycin resistant Staph aureus (VRSA)
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
150
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Assiut, Egypt, 71111
- Assiut University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
N/A
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
critically ill patients
Description
Inclusion Criteria:
- Intensive care patients
Exclusion Criteria:
- none
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Methicillin resistant staphylococcus aureus
|
effect silver nanoparticles will be examined on multidrug resistant bacteria
|
vancomycin resistent staphylococcus aureus
|
effect silver nanoparticles will be examined on multidrug resistant bacteria
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
bactericidal effect of silver nanoparticles on multidrug resistant bacteria
Time Frame: 24 hours
|
24 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 1, 2020
Primary Completion (Actual)
October 5, 2020
Study Completion (Actual)
October 13, 2020
Study Registration Dates
First Submitted
June 11, 2020
First Submitted That Met QC Criteria
June 11, 2020
First Posted (Actual)
June 16, 2020
Study Record Updates
Last Update Posted (Actual)
November 5, 2020
Last Update Submitted That Met QC Criteria
November 4, 2020
Last Verified
November 1, 2020
More Information
Terms related to this study
Other Study ID Numbers
- XXXXX (Université Laval)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multidrug Resistent Bacteria
-
University Hospital, GrenobleBecton, Dickinson and CompanyCompletedMultidrug-resistant Bacteria ScreeningFrance
-
Stephen HarbarthEuropean CommissionUnknownIntestinal Colonization With Multidrug-resistant BacteriaIsrael, Switzerland, France, Netherlands
-
Assistance Publique - Hôpitaux de ParisCompletedFecal Carriage of Multidrug-resistant BacteriaFrance
-
Seoul National University HospitalCompletedMultidrug-resistant Gram-negative Bacteria InfectionKorea, Republic of
-
MJM BontenParis 12 Val de Marne UniversityCompletedICU-ecology (Multidrug Resistant Bacteria) | ICU-acquired BacteraemiaBelgium, Spain, United Kingdom, Italy, Portugal, Slovenia
-
University Hospital, GrenobleCentre de Recherche en Nutrition Humaine Rhone-Alpe; Institut National de Recherche...Completed
-
Colgate PalmoliveCompleted
-
University of British ColumbiaCompleted
-
University of MichiganWayne State University; Henry Ford Health System; Agency for Healthcare Research... and other collaboratorsCompletedClostridium Difficile Infection | Healthcare Associated Infection | Infection Due to Multidrug Resistant BacteriaUnited States
-
Professional Disposables International, Inc.CompletedBacteria Microflora ReductionUnited States
Clinical Trials on silver nanoparticles
-
Washington University School of MedicineWithdrawnChronic Rhinosinusitis (Diagnosis)
-
Universidad Autonoma de San Luis PotosíUnknownTooth DemineralizationMexico
-
Universidad Autonoma de San Luis PotosíUnknown
-
Catholic University of the Sacred HeartISS, Dip.Tecnologie e Salute, Prof. Gianfranco DonelliCompletedCentral Venous Catheter Related InfectionsItaly
-
Universidad Autonoma de San Luis PotosíCompleted
-
Sohag UniversityUnknown
-
Bio-Cancer Treatment International LimitedThe University of Hong KongTerminated
-
Cairo UniversityCompleted
-
Minia UniversityCompleted
-
Ahmed A. H. AbdellatifUnknownInfection, Bacterial | Foot Infection FungalSaudi Arabia